middle.news
Cambium Bio Secures A$2.12M at 60% Premium to Fund Phase 3 Trials
2:47pm on Wednesday 30th of July, 2025 AEST
•
Healthcare
Read Story
Cambium Bio Secures A$2.12M at 60% Premium to Fund Phase 3 Trials
2:47pm on Wednesday 30th of July, 2025 AEST
Key Points
A$2.12 million raised via placement of 4.57 million shares at A$0.4637 each
Placement price represents a 59.9% premium to last closing share price
Da Jyun Capital Investment Corporation leads with A$2.07 million subscription
Funds earmarked for Phase 3 trials of Elate Ocular and working capital
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cambium Bio (ASX:CMB)
OPEN ARTICLE